-
1 day ago | 
targetedonc.com | Jordyn Sava
An updated analysis on larotrectinib (Vitrakvi) for patients with TRK fusion thyroid carcinoma showed compelling data on the agent’s efficacy and safety, including a high and durable response rate and a manageable safety profile.1 Of the 31 patients included in the analysis, the overall response rate (ORR) was 65% (95% CI, 45%-81%), which included 3 (10%) complete responses, 17 (55%) partial responses (PR), 5 (16%) cases of stable disease (SD), 4 (13%) cases of progressive disease (PD), and 2...
-
2 days ago | 
oncnursingnews.com | Jordyn Sava
A 14-gene molecular assay for the identification of high-risk patients with stage IA to IIA nonsquamous non–small cell lung cancer (NSCLC) most likely to derive benefit from adjuvant chemotherapy led to a significant increase in disease-free survival (DFS), according to results from the interim analysis of the international, multicenter, prospective, randomized AIM-HIGH trial (NCT01817192) presented at the 2025 American Society of Clinical Oncology Annual Meeting.1 At 24 months, 96% of...
-
2 days ago | 
targetedonc.com | Jordyn Sava
Results from the ongoing phase 1/2a EVICTION study (NCT04243499) of ICT01 in combination with azacitidine and venetoclax (Venclexta) for newly diagnosed acute myeloid leukemia (AML) are encouraging, demonstrating a complete response (CR) rate of 74% in older/unfit patients. This result nearly doubles the historical CR rates observed with azacitidine and venetoclax alone.
-
3 days ago | 
targetedonc.com | Jordyn Sava
Lutetium-177 (177Lu) vipivotide tetraxetan (177Lu PSMA-617; Pluvicto) in combination with hormone therapy provided a statistically significant and clinically meaningful benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen (PSMA)-positive metastatic hormone-sensitive prostate cancer (mHSPC) compared with hormone therapy alone, according to findings from the interim analysis of the phase 3 PSMAddition trial (NCT04720157).1 A promising...
-
4 days ago | 
targetedonc.com | Jordyn Sava
The new drug application (NDA) seeking full approval of ziftomenib (KO-539) in relapsed/refractory acute myeloid leukemia (AML) harboring an NPM1 mutation has received FDA priority review. A target action date of November 30, 2025, under the Prescription Drug User Fee Act (PDUFA), has been set by the FDA. Findings from the phase 1/2 KOMET-001 trial (NCT04067336) support this regulatory decision.
-
4 days ago | 
onclive.com | Jordyn Sava
Consolidation therapy with benmelstobart (TQB2450), with or without anlotinib, provided a substantive progression-free survival (PFS) benefit vs placebo in patients with unresectable stage III non–small cell lung cancer (NSCLC) who do not progress after chemoradiotherapy, according to findings from the phase 3 R-ALPS trial (NCT04325763) presented during the 2025 ASCO Annual Meeting.1 In this multicenter, double-blind study, 553 patients were randomly assigned following concurrent or...
-
5 days ago | 
targetedonc.com | Jordyn Sava
Early results from a phase 1 trial (NCT05701527) evaluating EBC-129 in advanced pancreatic ductal adenocarcinoma (PDAC) showed encouraging signs of clinical activity, with a 20% objective response rate (ORR), 71.4% disease control rate (DCR), and median progression-free survival (PFS) of 12.9 weeks in a population with heavily pretreated disease, according to data presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 Among 21 enrolled patients, most had received...
-
6 days ago | 
targetedonc.com | Jordyn Sava
Final results of the phase 3 CASSANDRA trial (NCT04793932) demonstrated that PAXG (cisplatin, nab-paclitaxel, gemcitabine, and capecitabine) is superior to modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant chemotherapy for the treatment of patients with resectable (R) or borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC).
-
1 week ago | 
targetedonc.com | Jordyn Sava
The combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) continues to demonstrate a sustained clinical benefit compared with standard chemotherapy or nivolumab monotherapy in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) metastatic colorectal cancer, according to updated results from the global phase 3 CheckMate-8HW trial (NCT04008030) presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.1 With a median follow-up...
-
1 week ago | 
targetedonc.com | Jordyn Sava
The interim analysis of the international, multicenter, prospective, randomized AIM-HIGH trial (NCT01817192) revealed a substantial improvement in disease-free survival (DFS) at 24 months for patients with stage IA to IIA nonsquamous non–small cell lung cancer (NSCLC) identified as high risk by a 14-gene molecular assay who received adjuvant chemotherapy, according to data presented at the 2025 American Society of Clinical Oncology Annual Meeting press briefing on Tuesday, May 27, 2025.1 At...
